- Article
Investigation of Pazopanib and Human Serum Albumin Interaction Using Spectroscopic and Molecular Docking Approaches
- Ahmet Cetinkaya,
- Mehmet Gokhan Caglayan,
- Mehmet Altay Unal,
- Pinar Beyazkilic,
- Caglar Elbuken,
- Esen Bellur Atici and
- Sibel A. Ozkan
Pazopanib (PAZ), a tyrosine kinase inhibitor, is used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). The FDA approved PAZ for RCC in 2009 and for STS in 2012. The antitumor activity of pazopanib, according to the...

